Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia

Cardiology Institute, Sheba Medical Center, Tel Aviv, Ramat-Gan, Israel.

When conventional treatment of patients with early clinical reinfarction after thrombolytic therapy fails, mechanical revascularization may be attempted. An alternative strategy, repeat thrombolytic infusions, is reported. Fifty-two patients with acute myocardial infarction were treated with one or two additional thrombolytic infusions of recombinant tissue-type plasminogen activator (rt-PA) because of nonsustained ischemia after initial treatment with rt-PA or streptokinase. Thirty-five patients received the second infusion within 1 h of the first; 13 patients received the second infusion 1 to 72 h after the first and 4 patients received it later during their hospitalization. Bleeding complications occurred in 10 patients (19%); however, most of these were minor (no intracranial bleeding) and only 2 patients required blood transfusion. In 14 patients in whom the decrease in fibrinogen and plasminogen levels was measured after the first and second infusions, this decrease was only 25% and 63%, respectively--only slightly higher than the 22% and 53% decreases measured in 63 patients who had only one rt-PA infusion. In 44 patients (85%), the acute ischemia resolved completely within 1 h after initiation of the second infusion. In 23 patients (44%), pain and ST segment elevation did not recur and invasive coronary intervention was avoided. Thus, repeat rt-PA infusions can stabilize a substantial number of patients with acute reinfarction and, even when relief is temporary, repeat rt-PA infusions can minimize myocardial damage while patients await mechanical revascularization.

This article has been cited by other articles:

				J.J. Edmond, J.K. French, P.E.G. Aylward, C.K. Wong, R.A.H. Stewart, B.F. Williams, C.G. De Pasquale, R.L. O'Connell, K. Van den Berg, F.J. Van de Werf, et al. Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2 Eur. Heart J., June 2, 2007; 28(12): 1418 - 1424. [Abstract] [Full Text] [PDF]

				P. W. Armstrong New advances in the management of acute coronary syndromes: 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarction Can. Med. Assoc. J., September 1, 2001; 165(6): 791 - 797. [Full Text] [PDF]

				P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 2 Circulation, June 19, 2001; 103(24): 2987 - 2992. [Full Text] [PDF]

				G. I. Barbash, Y. Birnbaum, K. Bogaerts, M. Hudson, E. Lesaffre, Y. Fu, S. Goodman, K. Houbracken, K. Munsters, C. B. Granger, et al. Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction : An Analysis of Outcome and Treatment Choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT 2) Studies Circulation, February 20, 2001; 103(7): 954 - 960. [Abstract] [Full Text] [PDF]